Pre-market: ALGBE.PA Global Bioenergies EURONEXT €0.0185 pre-Feb2 earnings: runway
ALGBE.PA stock trades at €0.0185 in pre-market Europe trading as investors brace for Global Bioenergies SA’s earnings on 2 Feb 2026. With a market cap of €335,375.00 and 50-day average €0.02, the small-cap utilities issuer faces scrutiny on cash runway, contract progress and revenue recognition. Ahead of the report, trading volume of 32,615 shares and a shallow order book increase the chance of outsized moves. We highlight the ratios, liquidity, and the key metrics analysts will watch in the Feb 2 release
ALGBE.PA stock: pre-earnings snapshot
ALGBE.PA stock is quoted at €0.0185 with a day low of €0.0185 and day high of €0.02. Average volume sits at 81,160 shares versus today’s 32,615, and the 50-day average price is €0.02 while the 200-day average is €0.31. The company is listed on EURONEXT in Europe and will report results on 2026-02-02; that calendar date is the immediate catalyst for pre-market positioning
ALGBE.PA stock: earnings calendar and what to watch
Global Bioenergies announces earnings on 2026-02-02; investors will watch revenue recognition, cash reserves and any updates on commercial contracts for isobutene. A clear update on production scale-up or third-party off-take would be a positive earnings catalyst. Management commentary on cash burn and expected breakeven timing will likely drive the first post-release trade
ALGBE.PA stock: fundamentals and key ratios
The firm reports EPS -€0.32 and a negative PE (reported -0.06). Balance-sheet metrics show cash per share €0.27 and book value per share €0.09, while debt-to-equity runs 3.34. Price-to-sales is 0.93 and price-to-book is 0.20, signaling market valuation low versus book. Current ratio is 1.47, indicating short-term liquidity is positive but tight given operating cash flow per share -€0.41
ALGBE.PA stock: technicals and liquidity ahead of the report
Technicals show RSI 39.56, ADX 17.33 (no clear trend) and Bollinger bands near €0.02, consistent with low volatility and thin liquidity. The 3-month price change is -47.89% and YTD change is -97.94%, reflecting steep depreciation. Traders should expect wider spreads: average volume 81,160 versus current 32,615 may amplify moves on any earnings surprise
ALGBE.PA stock: Meyka AI grade and analyst context
Meyka AI rates ALGBE.PA with a score out of 100: 68.53 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Third-party company rating shows a C with conservative DCF signals; consensus coverage is thin, which raises execution risk for investors
ALGBE.PA stock: risks, catalysts and outlook
Key downside risks include further dilution, missed contract milestones and continued negative operating cash flow. Catalysts include commercial agreements, progress on gas-fermentation pilots, or a clear path to industrial-scale production. Given the tiny market cap €335,375.00 and high debt-to-equity, volatility will remain elevated until management confirms funding or revenue traction
Final Thoughts
ALGBE.PA stock arrives into pre-market on 28 Jan 2026 at €0.0185 with an earnings release set for 2 Feb 2026. Our view balances high execution risk with structural opportunity in bio-based isobutene. Meyka AI’s forecast model projects €0.49, which versus the current €0.0185 implies an upside of 2,548.65%. For a pragmatic scenario we set a 12-month base case price target €0.10 (implied upside 440.54%) and a near-term target €0.05 (implied upside 170.27%). These targets reflect low liquidity, weak recent performance and the binary nature of results-driven catalysts. Forecasts are model-based projections and not guarantees. Investors should watch Feb 2 commentary on cash runway, confirmatory contracts, and potential dilution. For primary documents and filings, see the Global Bioenergies site and the Euronext listing. Meyka AI’s analysis aims to clarify the earnings risk-reward ahead of the report
FAQs
When does Global Bioenergies report earnings and why does it matter for ALGBE.PA stock?
Global Bioenergies reports on 2026-02-02. The update matters because investors expect clarity on revenue recognition, commercial contracts, and cash runway, all of which directly affect ALGBE.PA stock volatility and short-term valuation
What is Meyka AI’s grade for ALGBE.PA and what does it imply for investors?
Meyka AI rates ALGBE.PA 68.53 (Grade B, HOLD). The grade reflects mixed fundamentals, sector comparison and forecast inputs. It suggests monitoring earnings outcomes rather than initiating large positions
How does Meyka AI’s forecast compare to the current ALGBE.PA stock price?
Meyka AI’s forecast model projects €0.49 versus the current €0.0185, implying 2,548.65% upside. Forecasts are model-based projections and not guarantees
What are the biggest risks to ALGBE.PA stock in the earnings report?
Major risks include missed commercial milestones, further capital raises, negative operating cash flow, and lack of near-term revenue visibility. Any sign of increased dilution would pressure ALGBE.PA stock
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
